Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Aberrant activation of oncogenes or loss of tumour suppressor genes opposes malignant transformation by triggering a stable arrest in cell growth, which is termed cellular senescence. This process is finely tuned by both cell-autonomous and non-cell-autonomous mechanisms that regulate the entry of tumour cells to senescence. Whether tumour-infiltrating immune cells can oppose senescence is unknown. Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth. Mechanistically, we found that Gr-1(+) cells antagonize senescence in a paracrine manner by interfering with the senescence-associated secretory phenotype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA). Strikingly, Pten-loss-induced cellular senescence was enhanced in vivo when Il1ra knockout myeloid cells were adoptively transferred to PTEN null mice. Therapeutically, docetaxel-induced senescence and efficacy were higher in PTEN null tumours when the percentage of tumour-infiltrating CD11b(+)Gr-1(+) myeloid cells was reduced using an antagonist of CXC chemokine receptor 2 (CXCR2). Taken together, our findings identify a novel non-cell-autonomous network, established by innate immunity, that controls senescence evasion and chemoresistance. Targeting this network provides novel opportunities for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, during cancer development associated with accumulation of senescent cells, SASP can recruit immature myeloid cells to promote tumorigenesis in a paracrine manner160,161.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [160]
In the citing paper
“Further, the SASP can recruit immature immune-suppressive myeloid cells to prostate and liver tumors (Di Mitri et al., 2014; Eggert et al., 2016) and stimulate tumorigenesis by driving angiogenesis and metastasis (Coppe ´ et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Di Mitri et al., 2014
In the citing paper
“In some instances, the SASP can also have immunosuppressive functions (Di Mitri et al. 2014; Eggert et al. 2016).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Di Mitri et al. 2014
In the citing paper
“Notably, data from various mouse models indicate that disrupting the CXCR1/2–MDSC axis in tumours is therapeutically efficacious across a wide variety of solid cancers166–172.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [167]
In the citing paper
“There is convergent evidence that this occurs via the recruitment of myeloid-derived suppressor cells (MDSCs) chemoattracted by factors (e.g., IL-6, IL-8, and CCL2) secreted by senescent cells in murine models of HCC, 193 prostate, 194 and skin cancers.195”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [194]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Self-citationOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124
Self-citation
Cited by
Items 101–200 of 409
Zhang, F., Guo, J., Yu, S., Zheng, Y., Duan, M., Zhao, L., Wang, Y., Yang, Z., & Jiang, X. (2024) · 癌症:英文版 · doi:10.1002/cac2.12591 · Cited by 112
Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
Frey, N., Venturelli, S., Zender, L., & Bitzer, M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.146 · Cited by 97
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
The tumor microenvironment and immune responses in prostate cancer patients
Kwon, J., Bryant, R. J., & Parkes, E. E. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0149 · Cited by 109
“It has been evidenced that PTEN null prostate tumours, through NFKB and JAK2/STAT3 signalling, can give rise to a senescence-associated secretory phenotype (SASP) geared towards the recruitment of MDSCs rather than lymphocytes (Toso et al. 2014).”
BackgroundInfluentialGulhati, P., Schalck, A. P., Jiang, S., Shang, X., Wu, C., Hou, P., Ruiz, S. H., Soto, L. M. S., Parra, E. R., Ying, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00500-z · Cited by 128
Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer
Mitri, D. D., & Alimonti, A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.005 · Cited by 100
Self-citationInfiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Lerman, I., García-Hernández, M. D. L. L., Rangel‐Moreno, J., Chiriboga, L. A., Pan, C., Nastiuk, K. L., Krolewski, J. J., Sen, A., & Hammes, S. R. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0003 · Cited by 98
“In fact, increased tumor infiltration of CD33þ MDSCs is correlated with human prostate cancer progression and diminishedoverall survival (26, 29).”
BackgroundInfluentialMetastases in Immune-Mediated Dormancy: A New Opportunity for Targeting Cancer
Romero, I., Garrido, F., & Garcia-Lora, A. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2406 · Cited by 86
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 98
Colucci, M., Zumerle, S., Bressan, S., Gianfanti, F., Troiani, M., Valdata, A., D’Ambrosio, M., Pasquini, E., Varesi, A., Cogo, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.004 · Cited by 93
Self-citationMurthy, P., Zenati, M. S., Abbas, A. I. A., Rieser, C. J., Bahary, N., Lotze, M. T., Zeh, H. J., Zureikat, A. H., & Boone, B. A. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08094-0 · Cited by 93
“Neutrophils also revert cancer cell senescence and promote immune evasion with inhibition of T cell activation and proliferation as well as recruitment of regulatory T cells.(40,41) Neutrophil extracellular trap (NET) formation, whereby neutrophils produce extracellular webs of DNA, histones, and granule proteins, has…”
BackgroundNon-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy.
Saleh, T., Tyutynuk-Massey, L., Cudjoe, E. K., Idowu, M. O., Landry, J. W., & Gewirtz, D. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00164 · Cited by 85
“Subsequent studies showed that reducing myeloid cell recruitment using a CXCR2 antagonist improved the ability of docetaxel to induce TIS, thereby enhancing its therapeutic effects (122).”
BackgroundWang, W., Yang, F., Zhang, L., Wang, M., Yin, L., Dong, X., Xiao, H., & Xing, N. (2023) · Advanced Materials · doi:10.1002/adma.202308762 · Cited by 98
Cellular senescence and the host immune system in aging and age-related disorders
Giannoula, Y., Kroemer, G., & Pietrocola, F. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.02.001 · Cited by 79
“In support of the latter scenario, phenomena of senescencerelated ‘immunosuppressive inflammation’ have been thoroughly described in the different mouse models of cancer, in which senescent neoplastic or stromal cells skewed adaptive immune responses via the recruitment of myeloid derived suppressor cells (MDSC) [87].”
BackgroundInfluentialKumar, R., Geuna, E., Michalarea, V., Guardascione, M., Naumann, U., Lorente, D., Kaye, S. B., & Bono, J. S. D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.67 · Cited by 78
“Di Mitri et al (2014) have shown in PTENnull prostate tumours in mice that CD11bþ /Gr-1þ myeloid cells prevent tumour senescence through secretion of IL-1RA and that CD11bþ /Gr-1þ myeloid cells can be reduced using a CXCR2 antagonist, encouraging tumour senescence following docetaxel. analysis for…”
BackgroundMolecular Regulation of Bone Metastasis Pathogenesis
Wu, M., Li, C.-J., Yiang, G., Cheng, Y., Tsai, A. P., Hou, Y.-T., Ho, Y.-C., Hou, M., & Chu, P. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489184 · Cited by 79
Liu, Y., Lomeli, I., & Kron, S. J. (2024) · Cells · doi:10.3390/cells13151281 · Cited by 77
The Engagement Between MDSCs and Metastases: Partners in Crime
Trovato, R., Canè, S., Petrova, V., Sartoris, S., Ugel, S., & Sanctis, F. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00165 · Cited by 79
“PMNMDSCs can also block senescence in cancer cells by promoting their growth through the release of IL-1 receptor antagonist (109) or S100A9-expressing exosomes (110).”
BackgroundPro- and anti-tumorigenic functions of the senescence-associated secretory phenotype
Lau, L., & David, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1565658 · Cited by 70
“In particular, in Pten-deficient mouse prostate tumors, induction of senescence via docetaxel paired with a CXCR2 antagonist, which blocks the recruitment of Gr-1+ myeloid cells, resulted in increased senescence coupled with a marked reduction of tumor cell size [79].”
BackgroundWu, W., Sun, H.-W., Chen, J., Ouyang, H., Yu, X.-J., Chen, H., Shuang, Z., Shi, M., Wang, Z., & Zheng, L. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0902 · Cited by 74
Self-citationOkuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
Brina, D., Ponzoni, A. A., Troiani, M., Calì, B., Pasquini, E., Attanasio, G., Mosole, S., Mirenda, M., D’Ambrosio, M., Colucci, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00594-z · Cited by 75
Self-citationSahu, S. K., Reddy, P., Lu, J. Y., Shao, Y., Wang, C., Tsuji, M., Núñez‐Delicado, E., Esteban, C. R., & Belmonte, J. C. I. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg1777 · Cited by 78
Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword
Battram, A. M., Bachiller, M., & Martín-Antonio, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124346 · Cited by 70
Dang, T., & Liou, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-26143-8 · Cited by 67
Wang, J., Wu, Y., Gao, W., Li, F., Bo, Y., Zhu, M., Fu, R., Liu, Q., Wen, S., & Wang, B. (2017) · Journal of Cancer · doi:10.7150/jca.17444 · Cited by 65
“MACS is a highly specific cell separation technology commonly used in cancer research, immunology, neuroscience, and stem cell research[19-21].”
BackgroundLin, L., Chen, S., Wang, H., Gao, B., Kallakury, B., Bhuvaneshwar, K., Cahn, K., Gusev, Y., Wang, X., Wu, Y., et al. (2021) · Theranostics · doi:10.7150/thno.49819 · Cited by 64
“In PTEN null mice, a massive infiltration of CD11b+Gr-1+ myeloid cells in a prostate tumor site can protect a fraction of tumor cells from senescence [54].”
BackgroundRoles of Apoptosis and Cellular Senescence in Cancer and Aging
Cerella, C., Grandjenette, C., Dicato, M. A., & Diederich, M. F. (2016) · Current Drug Targets · doi:10.2174/1389450116666150202155915 · Cited by 71
Senescence and cancer: An evolving inflammatory paradox
Ruhland, M. K., Coussens, L. M., & Stewart, S. A. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.001 · Cited by 60
“Interestingly, there is now evidence that this interplay between senescent cells and immune cells is bidirectional given that tumorinfiltrating Gr-1+ myeloid cells can antagonize senescence induction within tumor epithelium (16).”
Espinoza, J. A., Jabeen, S., Batra, R., Papaleo, E., Haakensen, V. D., Wielenga, V. T., Talman, M., Brünner, N., Børresen‐Dale, A., Gromov, P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248015 · Cited by 73
“It was recently demonstrated that IL-1RA that is synthesized by Gr-1C myeloid cells is able to prevent the onset of senescence in a PTEN-null prostate tumor model.(38) In the same study, patients with high levels of IL-1RA did not respond to chemotherapy and experienced a shorter DFS period compared with patients with…”
ResultInfluentialXiong, J., Dong, L., Lv, Q., Yin, Y., Zhao, J., Ke, Y., Wang, S., Zhang, W., & Wu, M. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1772 · Cited by 66
Bedeschi, M., Marino, N., Cavassi, E., Piccinini, F., & Tesei, A. (2023) · Cells · doi:10.3390/cells12050802 · Cited by 65
Targeting PML in triple negative breast cancer elicits growth suppression and senescence
Arreal, L., Piva, M., Fernández, S., Revandkar, A., Schaub-Clerigué, A., Villanueva, J., Zabala‐Letona, A., Pujana-Vaquerizo, M., Astobiza, I., Cortázar, A. R., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0407-5 · Cited by 61
Self-citationCellular senescence or stemness: hypoxia flips the coin
Otero-Albiol, D., & Carnero, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02035-0 · Cited by 58
A QSP model of prostate cancer immunotherapy to identify effective combination therapies
Coletti, R., Leonardelli, L., Parolo, S., & Marchetti, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-65590-0 · Cited by 58
Xia, S., Wu, J., Zhou, W., Zhang, M., Zhao, K., Liu, J., Tian, D., & Liao, J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03853-y · Cited by 62
Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer
Banerjee, P., Kotla, S., Velatooru, L. R., Abe, R. J., Olmsted‐Davis, E. A., Cooke, J. P., Schadler, K., Deswal, A. M., Herrmann, J., Lin, S. H., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.763930 · Cited by 57
Therapy-induced senescence as a component of tumor biology: Evidence from clinical cancer
Saleh, T., Bloukh, S., Hasan, M., & Shboul, S. A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188994 · Cited by 56
Shang, J., Xiao, H., Zha, H., Tao, H., Li, X., Yuan, F., Chen, G., Wang, L., Ma, J., & Hu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.585271 · Cited by 58
“Additionally, neutrophils also revive the senescent cancer cell and suppress T cell activation to promote immune evasion (38).”
BackgroundDiverse Neutrophil Functions in Cancer and Promising Neutrophil-Based Cancer Therapies
Sounbuli, K., Mironova, N. L., & Alekseeva, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415827 · Cited by 55
Du, M., Sun, L., Guo, J. J., & Lv, H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107198 · Cited by 57
Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer
Wang, H., Wang, S., Huang, M.-C., Liang, X., Tang, Y.-J., & Tang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00498 · Cited by 61
Hu, X., & Zhang, H. (2019) · Medical Science Monitor · doi:10.12659/msm.914295 · Cited by 58
“For example, CD11b+ gr-1+ myeloid-derived suppressor cells could enhance the senescence evading of tumor cells and promote their proliferation by secreting the antagonistic molecule IL1RA of IL1R [12].”
BackgroundOvercoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 59
Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity
Saxena, S., & Singh, R. K. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09970-6 · Cited by 57
Udumula, M. P., Sakr, S., Dar, S. A., Alvero, A. B., Ali‐Fehmi, R., Abdulfatah, E., Li, J., Jiang, J., Tang, A., Buekers, T., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101272 · Cited by 57
Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia
Hanna, B. S., Öztürk, S., & Seiffert, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.014 · Cited by 56
Lecavalier‐Barsoum, M., Chaudary, N., Han, K. C.-Z., Koritzinsky, M., Hill, R. P., & Milosevic, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31297 · Cited by 55
Guo, Z., Zhang, Y., Gong, Y., Li, G., Pan, J., Dou, D., Ma, K., Cui, C., Liu, Y., & Zhu, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.029 · Cited by 56
Cellular senescence in cancer: molecular mechanisms and therapeutic targets
Jin, P., Duan, X., Li, L., Zhou, P., Zou, C., & Xie, K. (2024) · MedComm · doi:10.1002/mco2.542 · Cited by 57
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Mitri, D. D., Toso, A., & Alimonti, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2261 · Cited by 50
“Intriguingly senescence evasion by MDSCs is promoted through the secretion in the tumor microenvironment of IL1RA which is capable to block IL1 signalling, needed for the execution of senescence in Pten null K-Ras tumors (15).”
BackgroundSelf-citationEmerging Role of the Unfolded Protein Response in Tumor Immunosurveillance
Vanacker, H., Vetters, J., Moudombi, L., Caux, C., Janssens, S., & Michallet, M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.05.005 · Cited by 53
“The composition of the SASP may vary according to the cell type or the oncogene, shaping an either immunogenic [52,53] or tolerogenic [54] effect on immune cells.”
Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy
Sai, B., & Xiang, J. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13867 · Cited by 57
“tional immunosuppressive cells, such as MDSCs, Tregs and Bregs, are involved in the maintenance of DTC dormancy in the bone marrow.(86,87) This balanced state may be disturbed by both changes in the DTCs (eg, additional mutations or epigenetic modifications in”
BackgroundLiu, P., Tang, Q., Chen, M., Chen, W., Lu, Y., Liu, Z., & He, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589908 · Cited by 56
“In contrast, tumor-infiltrating myeloid-derived suppressive cells (MDSCs) hinder senescence induction and spread through the secretion of interleukin 1 (IL-1) receptor antagonist within tumor microenvironment, and thereby interfering with IL-1a signaling pathway (66).”
BackgroundConnecting the dots: Neutrophils at the interface of tissue regeneration and cancer
Nolan, E., & Malanchi, I. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2022.101598 · Cited by 55
Conteduca, V., Crabb, S. J., Jones, R. J., Caffo, O., Elliott, T., Scarpi, E., Fabbri, P., Derosa, L., Massari, F., Numico, G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158952 · Cited by 53
Nanotechnology reinforced neutrophil-based therapeutic strategies for inflammatory diseases therapy
Wu, J., Ma, T., Zhu, M., Huang, T., Zhang, B., Gao, J.-Q., & Lin, N. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101577 · Cited by 48
Immunometabolism and oxidative stress: roles and therapeutic strategies in cancer and aging
Zhou, N.-J., Bao, W.-Q., Zhang, C., Jiang, M., Liang, T.-L., Ma, G.-Y., Liu, L., Pan, H., & Li, R.-Z. (2025) · npj Aging · doi:10.1038/s41514-025-00250-z · Cited by 50
“In aging tissues, Tregs suppress immune responsesbyinducingsenescenceineffectorTcells 139,140 ,whereasMDSCsin tumors block T cell activation through molecules like IL-1RA 138,141 .”
Tumor-associated myeloid cells as guiding forces of cancer cell stemness
Sica, A., Porta, C., Amadori, A., & Pastò, A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1997-8 · Cited by 50
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
Piro, G., Carbone, C., Carbognin, L., Pilotto, S., Ciccarese, C., Iacovelli, R., Milella, M., Bria, E., & Tortora, G. (2019) · Cancers · doi:10.3390/cancers11101525 · Cited by 48
“At this stage, PTEN-null lesions showed a concomitant presence of both senescent and proliferative cells; however, the massive infiltration of MDSCs induced secretion of interleukin-1 receptor antagonist (IL-1RA), which hampered the senescence response, thus sustaining tumor growth [31].”
BackgroundCDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati, A., D’Ambrosio, M., Troiani, M., Mosole, S., Pellegrini, L., Chen, J., Revandkar, A., Bolis, M., Theurillat, J.-P. P., Guccini, I., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131133 · Cited by 47
“Prostate sections of the various genotypes (WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/–) were analyzed for senescence response by performing SA-β-gal and p-HP1γ staining, 2 markers of senescence in vivo (45).”
MethodSelf-citationRiess, C., Irmscher, N., Salewski, I., Strüder, D., Classen, C.-F., Große-Thie, C., Junghanß, C., & Maletzki, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09940-4 · Cited by 50
Zeng, W., Liu, H., Mao, Y., Jiang, S., Hao, Y., Zhang, Z., Wang, M., & Zong, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5673 · Cited by 49
“Moreover, MDSCs directly aid in the survival of metastatic cancer cells (143) and secrete IL‑1 receptor antagonists to counteract cancer cell senescence (147).”
BackgroundSelf-citationKalathur, M., Toso, A., Chen, J., Revandkar, A., Danzer-Baltzer, C., Guccini, I., Alajati, A., Sarti, M., Pinton, S., Brambilla, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms8227 · Cited by 44
Self-citationThe nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein
Chen, M., Nowak, D. G., Narula, N., Robinson, B. D., Watrud, K. E., Ambrico, A. J., Herzka, T. M., Zeeman, M. E., Minderer, M., Zheng, W., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201604025 · Cited by 45
Anthracycline chemotherapy‐mediated vascular dysfunction as a model of accelerated vascular aging
Clayton, Z. S., Hutton, D. A., Mahoney, S. A., & Seals, D. R. (2021) · Aging and Cancer · doi:10.1002/aac2.12033 · Cited by 49
Mahmud, Z., Rahman, A., Mishu, I. D., & Kabir, Y. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10024-8 · Cited by 46
PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo
Parisotto, M., Grelet, E., El Bizri, R., Dai, Y., Terzic, J., Eckert, D., Gargowitsch, L., Bornert, J.-M., & Metzger, D. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171207 · Cited by 43
“Di Mitri et al. reported that GR1-positive myeloid cells infiltrate the prostate of PTENpe−/− mice and secrete the cytokine IL-1RA, an antagonist of IL-1R, which opposes PICS in a paracrine fashion (Di Mitri et al., 2014).”
BackgroundResultInfluentialThe recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ren, R., Xiong, C., Ma, R., Wang, Y., Yue, T., Yu, J., & Shao, B. (2023) · MedComm · doi:10.1002/mco2.323 · Cited by 47
Chen, Z., Zhou, J., Wu, Y., Chen, F., Li, J., Tao, L., Tian, Y., Wang, H., Li, Z., Li, Z., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02956-y · Cited by 47
Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions
Sody, S., Uddin, M., Grüneboom, A., Görgens, A., Giebel, B., Gunzer, M., & Brandau, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01419 · Cited by 48
Neutrophils: Critical components in experimental animal models of cancer
Hagerling, C., & Werb, Z. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.02.003 · Cited by 44
Aging tumour cells to cure cancer: “pro-senescence” therapy for cancer
Calcinotto, A., & Alimonti, A. (2017) · Swiss Medical Weekly · doi:10.57187/smw.2017.14367 · Cited by 45
Self-citationPolymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer
Wen, J., Huang, G., Liu, S., Wan, J., Wang, X., Zhu, Y., Kaliney, W. J., Zhang, C., Liang Cheng, C., Wen, X., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.160 · Cited by 46
“This result suggests that paracrine signaling between PMN-MDSCs and PCa cells through IL-1Ra and IL-23 [6,8] should require efficient cytokine diffusion.”
BackgroundMa, Z., Zhang, C., Liu, X., Fang, F., Liu, S., Liao, X., Tao, S., & Mai, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-64947-9 · Cited by 42
Wang, J., Bo, X., Suo, T., Liu, H., Ni, X., Shen, S., Li, M., Xu, J., Liu, H., & Wang, Y. (2018) · Cancer Science · doi:10.1111/cas.13627 · Cited by 41
“This method may improve survival of biliary cancer patients with high TIN, which is in line with findings that neutrophil depletion by C-X-C chemokine receptor type 2 (CXCR2) blockage can improve tumor inhibition of chemotherapy.(13,46,47) As reported previously, neutrophils can suppress CD8 + T cellmediated antitumor…”
BackgroundImmune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 41
“Conversely, Gr-1-expressing myeloid cells may also promote tumor growth by interfering with the senescence-associated secretory phenotype of cancer cells (Di Mitri et al. 2014).”
BackgroundSex steroids in the tumor microenvironment and prostate cancer progression
Boibessot, C., & Toren, P. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0493 · Cited by 40
Autophagy inhibition signals through senescence to promote tumor suppression
Peng, N., Kang, H. H., Feng, Y., Minikes, A. M., & Jiang, X. (2022) · Autophagy · doi:10.1080/15548627.2022.2155794 · Cited by 39
Su, Y. J., Leng, M., Yang, Q., Jiang, W., Xiang, G., Long, L., & Zhou, X. W. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03522-8 · Cited by 38
“Additionally, IL-1RA disrupts the senescence-associated secretory phenotype of tumors, protecting proliferating tumor cells from senescence regulation in a paracrine manner [70]; IL-10 enhances distant metastasis by activating the c-Met/STAT3 signaling pathway [71].”
Wang, H., Yu, Y., Li, R., Zhang, H., Chen, Z., Sun, C., & Zhuang, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.022 · Cited by 43
“For instance, in prostate cancer models, inhibitors of CSF-1R, CCR2, and CXCR2 have been employed to block the recruitment and infiltration of senescent-induced suppressive myeloid cell populations 12-14 .”
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
Clappaert, E. J., Murgaski, A., Damme, H. V., Kiss, M., & Laoui, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02250 · Cited by 41
Edwards, C. M., & Johnson, R. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644303 · Cited by 39
“Comparison of the skeletal effects induced by daily administration of PTHrP (1-36) and PTHrP (107-139) to ovariectomized mice.”
BackgroundLi, X., Li, Y., Yu, Q., Qian, P., Huang, H., & Lin, Y. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0421-597rr · Cited by 41
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
van Schaik, T., Chen, K., & Shah, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.678562 · Cited by 38
“These antibodies are safe for use in human patients (189) and decrease the infiltration of MDSCs in murine solid tumors (190).”
BackgroundInfluentialLiu, G., Chen, Y., Qi, F., Jia, L., Lu, X., He, T., Fu, Y., Li, L., & Luo, Y. (2015) · The Journal of Pathology · doi:10.1002/path.4564 · Cited by 37
“After the tumour volume had reached 200 mm3, the mice were treated with drugs: paclitaxel (25 mg/kg) [23], doxorubicin (5 mg/kg) [24], carboplatin (50 mg/kg) [25], fluorouracil (50 mg/kg) [24] (all chemo-drugs were administered in a single dosage), or SB265610 (2 mg/kg, once daily) [26], AMD3100 (1.”
MethodTumor-Induced Myeloid-Derived Suppressor Cells
Sanctis, F. D., Bronte, V., & Ugel, S. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0016-2015 · Cited by 39
Autophagy and senescence in cancer therapy
Patel, N. H., Bloukh, S., Alwohosh, E., Alhesa, A., Saleh, T., & Gewirtz, D. A. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.01.002 · Cited by 42
Immune Cell Migration to Cancer
Ryan, A. T., Kim, M., & Lim, K. (2024) · Cells · doi:10.3390/cells13100844 · Cited by 38
IL-22 Signaling in the Tumor Microenvironment
Jiang, R., & Sun, B. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-55617-4_5 · Cited by 35
Emergency myelopoiesis in solid cancers
Aliazis, K., Yenyuwadee, S., Phikulsod, P., & Boussiotis, V. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19656 · Cited by 36
Cao, J., Chen, Q., Bai, X., Liu, L., Ma, W., Lin, C., Lu, F., Zhou, T., Zhan, J., Huang, Y., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2280002 · Cited by 34
Application of Anti-Inflammatory Agents in Prostate Cancer
Hatano, K., Fujita, K., & Nonomura, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082680 · Cited by 33
Heterogeneity of neutrophils in cancer: one size does not fit all
Chen, S., Zhang, Q., Lu, L., Xu, C., Li, J., Zha, J., Ma, F., Luo, H. R., & Hsu, A. Y.-H. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0426 · Cited by 35
The Power Behind the Throne: Senescence and the Hallmarks of Cancer
Hoare, M., & Narita, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050352 · Cited by 33
Identification of docetaxel‐related biomarkers for prostate cancer
Peng, Y., Dong, S., Yang, Z., Song, Y., Ding, J., Hou, D., Wang, L., Zhang, Z., Li, N., & Wang, H. (2021) · Andrologia · doi:10.1111/and.14079 · Cited by 34
Self-citationTargeting myeloid-derived suppressor cells for cancer therapy
Tang, H., Li, H., & Sun, Z. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0806 · Cited by 38
Understanding cellular senescence: pathways involved, therapeutics and longevity aiding
Kumar, A., & Thirumurugan, K. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2287929 · Cited by 31
Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?
Cai, X., Guillot, A., & Liu, H. (2022) · Cells · doi:10.3390/cells12010132 · Cited by 38
Metadata
- Authors
- Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., Da Silva-Alvarez, S., Collado, M., Eisenberger, M., Zhang, Z., Catapano, C., Grassi, F., & Alimonti, A.
- Affiliations
- Institute of Oncology Research (CH)
- Institute for Research in Biomedicine (CH)
- Complejo Hospitalario Universitario de Santiago (ES)
- Johns Hopkins University (US)
- University of Milan (IT)
- Corresponding author
- Alimonti, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-08-24
- Volume
- 515
- Issue
- 7525
- Pages
- 134-137
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1968545383
- Cited by
- 388
- References
- 32
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 31 · 2023: 39 · 2022: 35 · 2021: 32 · 2020: 44 · 2019: 22 · 2018: 33 · 2017: 30 · 2016: 26 · 2015: 23 · 2014: 3
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IRIS (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, senescence evasion, interleukin-1 receptor antagonist, senescence-associated secretory phenotype, chemoresistance, docetaxel, CXCR2 antagonist, innate immunity, tumor microenvironment
- MeSH terms
- Docetaxel, Animals, Cell Movement, Humans, Immunity, Innate, Male, Prostatic Neoplasms, Cellular Senescence, Disease Progression, Drug Resistance, Neoplasm, Tumor Escape, Receptors, Chemokine, Myeloid Cells, Receptors, Interleukin-8B, Taxoids, PTEN Phosphohydrolase, Mice, Interleukin-1alpha, Interleukin 1 Receptor Antagonist Protein, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.